Search Clinical Trials in the European Union

Duration
Visits
Efficacy phase (II)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1041-1060 of 1,738 trials

COPD: Dronabinol for Breathlessness Relief

We are studying whether Dronabinol can help people with severe and very severe COPD experience less breathlessness. This trial will compare its effects against a placebo.

Chronic Obstructive Pulmonary Disease≤3 monthsEfficacy phase (II)Confirmation phase (III)Post-Trial Drug AccessStandard MedicinesInternal MedicinePulmonology

Pulmonary Arterial Hypertension: LTP001 Treatment Study

We are studying a new treatment called LTP001 in healthy adults and in individuals with pulmonary arterial hypertension. The goal is to evaluate its safety and how well it may improve exercise capacity and overall health.

Pulmonary Arterial HypertensionSafety phase (I)Efficacy phase (II)16-20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyPulmonology

Myomectomy: Misoprostol for Reducing Blood Loss

We are studying whether misoprostol can help reduce blood loss during myomectomy surgeries. This trial involves comparing its effects against a placebo in patients undergoing different surgical techniques.

Uterine FibroidsEfficacy phase (II)Standard MedicinesGynecology and Obstetrics

Advanced Solid Tumors: MCLA-158 (Petosemtamab) Study

We are testing a new treatment called MCLA-158 for people with advanced solid tumors to see how well it works and how safe it is. This study looks at its effects alone and in combination with other therapies.

Metastatic Colorectal CancerMalignant Solid TumorSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesOncology

Skin Cancer Treatment: Nivolumab and Relatlimab Study

We are studying the effects of Nivolumab alone and in combination with Relatlimab for patients with advanced squamous cell carcinoma of the skin. This trial aims to find out which treatment may help control the disease better.

Locally Advanced/Metastatic Squamous Cell Carcinoma of the Skin>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesDermatologyOncology

Retinitis Pigmentosa: Stem Cell Eye Treatment

We are testing a new stem cell-based treatment for people with retinitis pigmentosa to see if it is safe and tolerable. The study also aims to evaluate its potential to improve vision.

Retinitis Pigmentosa1-2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesOphthalmology

Obesity: PF-07976016 Medication Study

We are testing a new medication called PF-07976016 to see if it helps adults with obesity lose weight more effectively than a placebo. The study also looks at the safety of this medication for those already taking liraglutide.

ObesityOverweight6-12 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesPartially RemoteDiabetologyEndocrinology

Idiopathic Inflammatory Myopathies: Upadacitinib Study

We are testing whether Upadacitinib can help patients with idiopathic inflammatory myopathies maintain stable disease after stopping IVIG treatment. The study compares its effects to a placebo over 16 weeks.

PolymyositisDermatomyositisAntisynthetase Syndrome3-6 monthsEfficacy phase (II)6-10 visitsStandard MedicinesDermatologyRheumatology

Osteoarthritis Behind the Kneecap: Nasal Cartilage Implantation

We are studying a new nasal cartilage treatment for people with osteoarthritis behind the kneecap to see if it improves recovery compared to standard care. The trial will also assess safety and how well the treatment works over time.

Knee OsteoarthritisPatellofemoral Osteoarthritis>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesInternal MedicineOrthopedics and Traumatology

Triple-Negative Breast Cancer: Ceralasertib with Durvalumab and Nab-Paclitaxel

We are studying a new treatment approach for patients with advanced triple-negative breast cancer who have relapsed after prior therapies. This trial aims to see if combining ceralasertib with other medications can improve their response to treatment.

Advanced Triple Negative Breast Cancer>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesOncology

Metastatic Colorectal Cancer: Trifluridine/Tipiracil with Panitumumab vs. Bevacizumab

We are studying two treatment combinations to find out which one works better for people with metastatic colorectal cancer. The trial also looks at safety and how treatments affect patients' quality of life.

Metastatic Colorectal Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesPartially RemoteOncology

Intrahepatic Cholangiocarcinoma: PUMP IV Trial

We are studying a new chemotherapy method to help prevent liver cancer from coming back after surgery. This trial will also look at side effects and how it affects patients' quality of life.

Intrahepatic Cholangiocarcinoma3-6 monthsEfficacy phase (II)6-10 visitsCost ReimbursementGastroenterologyHepatologyOncology

Angiosarcoma and Undifferentiated Pleomorphic Sarcoma: Propranolol and Pembrolizumab Study

We are studying the effects of a new treatment combining propranolol and pembrolizumab for patients with advanced Angiosarcoma and Undifferentiated Pleomorphic Sarcoma. The goal is to see if this combination improves survival and quality of life.

Advanced Angiosarcoma and Undifferentiated Pleomorphic Sarcoma3-6 monthsEfficacy phase (II)No PlaceboStandard MedicinesOncology

IDH1/IDH2-Mutant Glioma: Vorasidenib with Temozolomide

We are studying the safety and effectiveness of a new drug, vorasidenib, combined with temozolomide for patients with IDH1- or IDH2-mutant gliomas. This research aims to see if this combination can improve treatment outcomes.

IDH1-mutant GliomaIDH2-mutant Glioma>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Sickle Cell Disease: Hydroxycarbamide Tablets for Children

We are studying the effects of a twice-daily dose of Hydroxycarbamide in children with sickle cell disease. This trial aims to evaluate its safety, effectiveness, and how well children tolerate the treatment.

Sickle Cell Disease>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyPediatrics

Karonudib for Blood Cancers: Phase 1 Study

We are evaluating the safety and tolerability of Karonudib in patients with advanced blood cancers like Acute Myeloid Leukemia and Multiple Myeloma. This study aims to find the best dose and understand how well it works with other cancer treatments.

Blood Cancers>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesHematologyOncology

Kidney Transplant: Eight Treg Immunotherapy

We are testing a new treatment using expanded regulatory T cells for living donor kidney transplant recipients. The goal is to see if this approach is safe and may reduce the need for traditional immunosuppressive medications.

Chronic Kidney FailureSafety phase (I)Efficacy phase (II)16-20 visitsNo PlaceboInvestigational MedicinesInternal MedicineNephrology

Rare Cancers: Targeted Drug Study

We are exploring how well existing targeted cancer drugs work for patients with rare and hard-to-treat cancers. The study will also look at any serious side effects from these treatments.

Cancer>2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Knee Surgery Pain Relief: Nefopam Study

We are investigating whether an oral medication called nefopam can reduce morphine use after total knee replacement surgery. This study aims to improve pain management for adults recovering from this procedure.

Postoperative Pain After Knee Surgery>2 yearsSafety phase (I)Efficacy phase (II)Investigational MedicinesInternal MedicineOrthopedics and Traumatology

Leiomyosarcoma: Trabectedin vs. Gemcitabine

We are comparing two treatments, Trabectedin and Gemcitabine, for patients with advanced leiomyosarcoma who have already received chemotherapy. The goal is to see which treatment works better in slowing down cancer growth and improving survival.

Leiomyosarcoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology